SCIENTIFIC publications

/cun/en/investigacion/publicaciones-cientificas/areaMain/02
  • Delta-24-RGD combined with radiotherapy exerts a potent antitumor effect in diffuse intrinsic pontine glioma and pediatric high grade glioma models

    Martinez-Velez N (1,2,3), Marigil M (1,2,3,4), García-Moure M (1,2,3), Gonzalez-Huarriz M (1,2,3), Aristu JJ (1,5), Ramos-García LI (5), Tejada S (1,2,6), Díez-Valle R (1,2,6), Patiño-García A (1,2,3), Becher OJ (7), Gomez-Manzano C (8,9), Fueyo J (8,10), Alonso MM (11,12,13).

    (1) The Health Research Institute of Navarra (IDISNA), Pamplona, Navarra, Spain.
    (2) Program in Solid Tumors, Foundation for the Applied Medical Research, Pamplona, Navarra, Spain.
    (3) Department of Pediatrics, Clínica Universidad de Navarra, University of Navarra, CIMA Building, Avd. Pio XII, 55, Pamplona, Spain.
    (4) Division of Neurosurgery, Lariboisière University Hospital, 2 Rue Ambroise Paré, 75475, Paris, cedex 10, France.
    (5) Department of Radiation Oncology, Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain.
    (6) Department of Neurosurgery, Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain.
    (7) Department of Pediatrics, Northwestern University and Division of Pediatric Hematology-Oncology and Stem Cell Transplant, Ann & Robert H. Lurie Children's Hospital, Chicago, IL, USA.
    (8) Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    (9) Department of NeuroOncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    (10) Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    (11) The Health Research Institute of Navarra (IDISNA), Pamplona, Navarra, Spain.
    (12) Program in Solid Tumors, Foundation for the Applied Medical Research, Pamplona, Navarra, Spain.
    (13) Department of Pediatrics, Clínica Universidad de Navarra, University of Navarra, CIMA Building, Avd. Pio XII, 55, Pamplona, Spain.

    Acta Neuropathologica Communications 29 APRIL 2019

  • Does drug-induced sleep endoscopy affect surgical outcome? A multicenter study of 326 obstructive sleep apnea patients

    Pang KP (1), Baptista PM (2), Olszewska E (3), Braverman I (4), Carrasco-Llatas M (5), Kishore S (6), Chandra S (7), Yang HC (8), Wang CMZ (1), Chan YH (9), Pang KA (1), Pang EB (10), Rotenberg B (11).

    (1) Otolaryngology Department, Asia Sleep Centre, Paragon, Singapore.
    (2) Otolaryngology Department, Clinica Universidad de Navarra, Pamplona, Spain.
    (3) Ear, Nose, and Throat Department, Medical University of Bialystok, Bialystok, Poland.
    (4) Department of Otolaryngology-Head and Neck Surgery, Hillel Yaffe Medical Center, Technion Faculty Medicine, Haifa, Israel.
    (5) Ear, Nose, and Throat Department, Hospital Universitario Dr. Peset, Valencia, Spain.
    (6) Otolaryngology Department, Nova Specialty Hospital, Hyderabad, India.
    (7) Ear, Nose, and Throat Department, Belle Vue Clinic and Hospital, Kolkata, India.
    (8) Otolaryngology Department, Chonnam National University Hospital, Gwangju, South Korea.
    (9) Biostatistics Unit, School of Medicine, National University Singapore, Singapore.
    (10) Medicine Faculty, University of Glasgow, Glasgow, United Kingdom.
    (11) Otolaryngology Department, Western University, London, Ontario, Canada.

    Laryngoscope 17 APRIL 2019

  • Delayed Effect and Gain Restoration After Intratympanic Gentamicin for Menière's Disease

    Martin-Sanz E (1,2), Diaz JY (1,2), Esteban-Sanchez J (1,2), Sanz-Fernández R (1,2), Perez-Fernandez N (1,2).

    (1) Department of Otolaryngology, University Hospital of Getafe.
    (2) Department of Otolaryngology, Clinica Universidad de Navarra, Madrid, Spain.

    Otology & Neurotology 16 OCTOBER 2018

  • Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma

    Dimopoulos MA (1), San-Miguel J (2), Belch A (3), White D (4), Benboubker L (5), Cook G (6), Leiba M (7), Morton J (8), Ho PJ (9), Kim K (10), Takezako N (11), Moreau P (12), Kaufman JL (13), Sutherland HJ (14), Lalancette M (15), Magen H (16), Iida S (17), Kim JS (18), Prince HM (19), Cochrane T (20), Oriol A (21), Bahlis NJ (22), Chari A (23), O' Rourke L (24), Wu K (24), Schecter JM (25), Casneuf T (26), Chiu C (24), Soong D 24, Sasser AK (27), Khokhar NZ (24), Avet-Loiseau H (28), Usmani SZ (29).

    (1) The National and Kapodistrian University of Athens, Athens, Greece
    (2) Clínica Universidad de Navarra-CIMA, IDISNA, CIBERONC, Pamplona, Spain.
    (3) Department of Oncology, University of Alberta Cross Cancer Institute, Edmonton, Alberta, Canada.
    (4) QEII Health Sciences Center and Dalhousie University, Halifax, Nova Scotia, Canada.
    (5) Hôpital Bretonneau, Centre Hospitalier Régional Universitaire (CHRU), Tours, France.
    (6) St James Institute of Oncology, Leeds Teaching Hospitals NHS Trust and University of Leeds.
    (7) Sheba Medical Center, Tel Hasher, Ramat Gan, Israel.
    (8) Icon Cancer Care, South Brisbane, QLD, Australia.
    (9) Institute of Haematology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
    (10) Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul.
    (11) Dept of Hematology, National Hospital Organization Disaster Medical Center of Japan, Tachikawa.
    (12) Hematology, University Hospital Hôtel-Dieu, Nantes, France.
    (13) Winship Cancer Institute, Emory University, Atlanta, GA, USA.
    (14) Leukemia/Bone Marrow Transplant Program, University of British Columbia, Vancouver, British Columbia.
    (15) CHU de Québec Research Center, Faculty of Medicine, Laval University, Québec, Canada.
    (16) Institute of Hematol, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, Petah-Tikva.
    (17) Dept of Hematology/Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya.
    (18) Yonsei University College of Medicine, Severance Hospital, Seoul, South Korea.
    (19) Epworth HealthCare and Sir Peter MacCallum Department of Oncology, University of Melbourne.
    (20) Gold Coast University Hospital, Southport, QLD, Australia.
    (21) Institut Catalá Oncologia,Institut Josep Carreras,Hospital Germans Trias I Pujol, Barcelona.
    (22) University of Calgary, Arnie Charbonneau Cancer Institute, Calgary, AB, Canada.
    (23) Icahn School of Medicine at Mount Sinai, New York, NY, USA.
    (24) Janssen Research & Development, LLC, Spring House, PA, USA.
    (25) Janssen Research & Development, LLC, Raritan, NJ, USA.
    (26) Janssen Research & Development, Beerse, Belgium.
    (27) Genmab US, Inc, Princeton, NJ, USA.
    (28) Unite de Genomique du Myelome, IUC-Oncopole, Toulouse, France.
    (29) Levine Cancer Institute/Atrium Health, Charlotte, NC, USA.

    Haematologica 20 SEPTEMBER 2018

  • Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C

    Manzardo C (1), Londoño MC (1,2), Castells L (2,3), Testillano M (4), Montero J L (2,5), Peñafiel J (1), Subirana M (1), Moreno A (6), Aguilera V (7), González-Diéguez ML (8), Calvo-Pulido J (9), Xiol X (10), Salcedo M (11), Cuervas-Mons V (12), Sousa JM (13), Suarez F (14), Serrano T (15,16), Herrero JI (2,17), Jiménez M (18), Fernandez JR (4), Giménez C (9), Del Campo S (6), Esteban-Mur JI (2,3), Crespo G (1,2), Moreno A (1), de la Rosa G (19), Rimola A (1,2), Miro JM (1); FIPSE LT-HIV investigators.

    (1) Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona.
    (2) CIBEREHD.
    (3) Hospital Vall d'Hebrón, Universitat Autónoma de Barcelona, Barcelona.
    (4) Servicio de Digestivo. Hospital Universitario Cruces, Barakaldo.
    (5) Hospital Universitario Reina Sofía-IMIBIC Córdoba.
    (6) Hospital Universitario Ramón y Cajal-IRYCIS, Madrid.
    (7) Hospital Universitari La Fe, Valencia.
    (8) Hospital Universitario Central de Asturias, Oviedo.
    (9) Hospital Universitario Doce de Octubre, Madrid.
    (10) Hospital de Bellvitge-IDIBELL, University of Barcelona, L'Hospitalet de Llobregat, Barcelona.
    (11) Hospital General Universitario Gregorio Marañón, Madrid.
    (12) Hospital Universitario Puerta de Hierro, Madrid.
    (13) Hospital Universitario Virgen del Rocío, Sevilla.
    (14) Complejo Hospitalario Universitario, A Coruña.
    (15) Hospital Universitario Lozano Blesa, ISS Aragón, Zaragoza.
    (16) Hospital Universitario Lozano Blesa, Zaragoza.
    (17) Clínica Universidad de Navarra, IdiSNA, Pamplona.
    (18) Hospital Universitario Carlos Haya, Málaga.
    (19) Organización Nacional de Trasplantes, Madrid.

    American Journal of Transplantation 02 JULY 2018

you mayBE INTERESTED

WHAT TECHNOLOGY
DO WE USE?

The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OUR
PROFESSIONALS

The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.

Imagen profesionales de la Clínica Universidad de Navarra

WHY CHOOSE
THE CLINICA?

Learn why we are different from other healthcare centers. Quality, speed, comfort and results.

Imagen del edificio de la Clínica Universidad de Navarra